

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6673805

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
MATTHEW J. BERNETT	03/22/2021
JOHN DESJARLAIS	03/29/2021
MICHAEL HEDVAT	03/10/2021
SUZANNE SCHUBBERT	03/12/2021
CHRISTINE BONZON	03/26/2021
RUMANA RASHID	03/03/2021
RECEIVING PARTY DATA	
Name:	XENCOR, INC.
Street Address:	111 WEST LEMON AVENUE
City:	MONROVIA
State/Country:	CALIFORNIA
Postal Code:	91016
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	16600236
PCT Number:	US1955956
CORRESPONDENCE DATA	
Fax Number:	(415)442-1001
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	4154421000
Email:	leonor.rivera@morganlewis.com, sfipdocketing@morganlewis.com
Correspondent Name:	JENNIFER K. NG, PH.D.
Address Line 1:	MORGAN, LEWIS & BOCKIUS LLP
Address Line 2:	ONE MARKET, SPEAR STREET TOWER
Address Line 4:	SAN FRANCISCO, CALIFORNIA 94105
ATTORNEY DOCKET NUMBER:	067461-5205-US & WO
NAME OF SUBMITTER:	LEONOR RIVERA-HUERTA
SIGNATURE:	/Leonor Rivera-Huerta/
DATE SIGNED:	04/23/2021

PATENT

Total Attachments: 14

source=067461_5205_US_WO_Assignment_signed#page1.tif
source=067461_5205_US_WO_Assignment_signed#page2.tif
source=067461_5205_US_WO_Assignment_signed#page3.tif
source=067461_5205_US_WO_Assignment_signed#page4.tif
source=067461_5205_US_WO_Assignment_signed#page5.tif
source=067461_5205_US_WO_Assignment_signed#page6.tif
source=067461_5205_US_WO_Assignment_signed#page7.tif
source=067461_5205_US_WO_Assignment_signed#page8.tif
source=067461_5205_US_WO_Assignment_signed#page9.tif
source=067461_5205_US_WO_Assignment_signed#page10.tif
source=067461_5205_US_WO_Assignment_signed#page11.tif
source=067461_5205_US_WO_Assignment_signed#page12.tif
source=067461_5205_US_WO_Assignment_signed#page13.tif
source=067461_5205_US_WO_Assignment_signed#page14.tif

ASSIGNMENT OF PATENT APPLICATION

WHEREAS, **Matthew BERNETT**, resident of Monrovia, California, USA, **John DESJARLAIS**, resident of Pasadena, California, USA, **Michael HEDVAT**, resident of Encino, California, USA, **Suzanne SCHUBBERT**, resident of Long Beach, California, USA, **Christine BONZON**, resident of Los Angeles, California, USA and **Ramana RASHID**, resident of Temple City, California, USA, hereinafter referred to as "Assignors", are inventors of the invention described in the following patent applications:

Title of Invention: **PD-1 TARGETED IL-15/IL-15RALPHA FC FUSION PROTEINS AND USES IN COMBINATION THERAPIES THEREOF**

U.S. Patent Application No. **16/600,236**, filed October 11, 2019; and

International Application No. **PCT/US2019/055956**, filed October 11, 2019.

WHEREAS, Xencor, Inc., located at 111 West Lemon Avenue, Monrovia, California, 91016 United States of America hereinafter referred to as "ASSIGNEE," is desirous of acquiring an interest in the invention and application and in any U.S. Letters Patent and Registrations which may be granted on any patent application claiming priority from the same;

For good and valuable consideration, receipt of which is hereby acknowledged by Assignors, Assignors have assigned, and by these presents do assign to Assignee all right, title and interest in and to the invention and application and to all foreign counterparts (including patent, utility model and industrial designs), and in and to any Letters Patent and Registrations which may hereafter be granted on any patent application claiming priority from the same in the United States and all countries throughout the world, and to claim the priority from the application as provided by the Paris Convention. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignors had this Assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.

Assignors further agree that Assignors will, without charge to Assignee, but at Assignee's expense, (a) cooperate with Assignee in the prosecution of U.S. Patent applications and foreign counterparts on the invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including applications and instruments of transfer, and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the invention and improvements in any and all countries, and to vest title thereto in Assignee, or Assignee's successors and assigns.

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: 3/22/2021

Matthew J. Bennett
Matthew BERNETT

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____

John DESJARLAIS

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____

Michael HEDVAT

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____

Suzanne SCHUBBERT

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____

Christine BONZON

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____

Rumana RASHID

IN TESTIMONY WHEREOF, Assignee has signed his/her name on the dates indicated.

XENCOR, INC.

Date: _____

By: _____

Name: Bassil I. DAHIYAT

Title: President and Chief Executive Officer

ASSIGNMENT OF PATENT APPLICATION

WHEREAS, **Matthew BERNETT**, resident of Monrovia, California, USA, **John DESJARLAIS**, resident of Pasadena, California, USA, **Michael HEDVAT**, resident of Encino, California, USA, **Suzanne SCHUBBERT**, resident of Long Beach, California, USA, **Christine BONZON**, resident of Los Angeles, California, USA and **Rumana RASHID**, resident of Temple City, California, USA, hereinafter referred to as "Assignors", are inventors of the invention described in the following patent applications:

Title of Invention: **PD-1 TARGETED IL-15/IL-15RALPHA FC FUSION PROTEINS AND USES IN COMBINATION THERAPIES THEREOF**

U.S. Patent Application No. **16/600,236**, filed October 11, 2019; and

International Application No. **PCT/US2019/055956**, filed October 11, 2019.

WHEREAS, Xencor, Inc., located at 111 West Lemon Avenue, Monrovia, California, 91016 United States of America hereinafter referred to as "ASSIGNEE," is desirous of acquiring an interest in the invention and application and in any U.S. Letters Patent and Registrations which may be granted on any patent application claiming priority from the same;

For good and valuable consideration, receipt of which is hereby acknowledged by Assignors, Assignors have assigned, and by these presents do assign to Assignee all right, title and interest in and to the invention and application and to all foreign counterparts (including patent, utility model and industrial designs), and in and to any Letters Patent and Registrations which may hereafter be granted on any patent application claiming priority from the same in the United States and all countries throughout the world, and to claim the priority from the application as provided by the Paris Convention. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignors had this Assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.

Assignors further agree that Assignors will, without charge to Assignee, but at Assignee's expense, (a) cooperate with Assignee in the prosecution of U.S. Patent applications and foreign counterparts on the invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including applications and instruments of transfer, and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the invention and improvements in any and all countries, and to vest title thereto in Assignee, or Assignee's successors and assigns.

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____
Matthew BERNETT

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: 3/29/2021

John DESJARLAIS

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____
Michael HEDVAT

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____
Suzanne SCHUBBERT

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____
Christine BONZON

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____
Rumana RASHID

IN TESTIMONY WHEREOF, Assignee has signed his/her name on the dates indicated.

XENCOR, INC.

Date: _____ By: _____

Name: Bassil I. DAHIYAT

Title: President and Chief Executive Officer

ASSIGNMENT OF PATENT APPLICATION

WHEREAS, **Matthew BERNETT**, resident of Monrovia, California, USA, **John DESJARLAIS**, resident of Pasadena, California, USA, **Michael HEDVAT**, resident of Encino, California, USA, **Suzanne SCHUBBERT**, resident of Long Beach, California, USA, **Christine BONZON**, resident of Los Angeles, California, USA and **Rumana RASHID**, resident of Temple City, California, USA, hereinafter referred to as "Assignors", are inventors of the invention described in the following patent applications:

Title of Invention: **PD-1 TARGETED IL-15/IL-15RALPHA FC FUSION PROTEINS AND USES IN COMBINATION THERAPIES THEREOF**

U.S. Patent Application No. **16/600,236**, filed October 11, 2019; and

International Application No. **PCT/US2019/055956**, filed October 11, 2019.

WHEREAS, Xencor, Inc., located at 111 West Lemon Avenue, Monrovia, California, 91016 United States of America hereinafter referred to as "ASSIGNEE," is desirous of acquiring an interest in the invention and application and in any U.S. Letters Patent and Registrations which may be granted on any patent application claiming priority from the same;

For good and valuable consideration, receipt of which is hereby acknowledged by Assignors, Assignors have assigned, and by these presents do assign to Assignee all right, title and interest in and to the invention and application and to all foreign counterparts (including patent, utility model and industrial designs), and in and to any Letters Patent and Registrations which may hereafter be granted on any patent application claiming priority from the same in the United States and all countries throughout the world, and to claim the priority from the application as provided by the Paris Convention. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignors had this Assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.

Assignors further agree that Assignors will, without charge to Assignee, but at Assignee's expense, (a) cooperate with Assignee in the prosecution of U.S. Patent applications and foreign counterparts on the invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including applications and instruments of transfer, and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the invention and improvements in any and all countries, and to vest title thereto in Assignee, or Assignee's successors and assigns.

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____
Matthew BERNETT

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____
John DESJARLAIS

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: 3-10-21
Michael HEDVAT

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____
Suzanne SCHUBBERT

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____
Christine BONZON

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____
Rumana RASHID

IN TESTIMONY WHEREOF, Assignee has signed his/her name on the dates indicated.

XENCOR, INC.

Date: _____ By: _____

Name: Basil I. DAHIYAT

Title: President and Chief Executive Officer

ASSIGNMENT OF PATENT APPLICATION

WHEREAS, **Matthew BERNETT**, resident of Monrovia, California, USA, **John DESJARLAIS**, resident of Pasadena, California, USA, **Michael HEDVAT**, resident of Encino, California, USA, **Suzanne SCHUBBERT**, resident of Long Beach, California, USA, **Christine BONZON**, resident of Los Angeles, California, USA and **Rumana RASHID**, resident of Temple City, California, USA, hereinafter referred to as "Assignors", are inventors of the invention described in the following patent applications:

Title of Invention: **PD-1 TARGETED IL-15/IL-15RALPHA FC FUSION PROTEINS AND USES IN COMBINATION THERAPIES THEREOF**

U.S. Patent Application No. **16/600,236**, filed October 11, 2019; and

International Application No. **PCT/US2019/055956**, filed October 11, 2019.

WHEREAS, Xencor, Inc., located at 111 West Lemon Avenue, Monrovia, California, 91016 United States of America hereinafter referred to as "ASSIGNEE," is desirous of acquiring an interest in the invention and application and in any U.S. Letters Patent and Registrations which may be granted on any patent application claiming priority from the same;

For good and valuable consideration, receipt of which is hereby acknowledged by Assignors, Assignors have assigned, and by these presents do assign to Assignee all right, title and interest in and to the invention and application and to all foreign counterparts (including patent, utility model and industrial designs), and in and to any Letters Patent and Registrations which may hereafter be granted on any patent application claiming priority from the same in the United States and all countries throughout the world, and to claim the priority from the application as provided by the Paris Convention. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignors had this Assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.

Assignors further agree that Assignors will, without charge to Assignee, but at Assignee's expense, (a) cooperate with Assignee in the prosecution of U.S. Patent applications and foreign counterparts on the invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including applications and instruments of transfer, and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the invention and improvements in any and all countries, and to vest title thereto in Assignee, or Assignee's successors and assigns.

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____

Matthew BERNETT

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____

John DESJARLAIS


IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____

Michael HEDVAT

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: 3/12/2021


Suzanne SCHUBBERT

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____

Christine BONZON

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____

Rumana RASHID

IN TESTIMONY WHEREOF, Assignee has signed his/her name on the dates indicated.

XENCOR, INC.

Date: _____

By: _____

Name: Bassil I. DAHIYAT

Title: President and Chief Executive Officer

ASSIGNMENT OF PATENT APPLICATION

WHEREAS, Matthew BERNETT, resident of Monrovia, California, USA, John DESJARLAIS, resident of Pasadena, California, USA, Michael HEDVAT, resident of Encino, California, USA, Suzanne SCHUBBERT, resident of Long Beach, California, USA, Christine BONZON, resident of Los Angeles, California, USA and Rumana RASHID, resident of Temple City, California, USA, hereinafter referred to as "Assignors", are inventors of the invention described in the following patent applications:

Title of Invention: **PD-1 TARGETED IL-15/IL-15RALPHA FC FUSION PROTEINS AND USES IN COMBINATION THERAPIES THEREOF**

U.S. Patent Application No. 16/600,236, filed October 11, 2019; and

International Application No. PCT/US2019/055956, filed October 11, 2019.

WHEREAS, Xencor, Inc., located at 111 West Lemon Avenue, Monrovia, California, 91016 United States of America hereinafter referred to as "ASSIGNEE," is desirous of acquiring an interest in the invention and application and in any U.S. Letters Patent and Registrations which may be granted on any patent application claiming priority from the same:

For good and valuable consideration, receipt of which is hereby acknowledged by Assignors, Assignors have assigned, and by these presents do assign to Assignee all right, title and interest in and to the invention and application and to all foreign counterparts (including patent, utility model and industrial designs), and in and to any Letters Patent and Registrations which may hereafter be granted on any patent application claiming priority from the same in the United States and all countries throughout the world, and to claim the priority from the application as provided by the Paris Convention. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignors had this Assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.

Assignors further agree that Assignors will, without charge to Assignee, but at Assignee's expense, (a) cooperate with Assignee in the prosecution of U.S. Patent applications and foreign counterparts on the invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including applications and instruments of transfer, and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the invention and improvements in any and all countries, and to vest title thereto in Assignee, or Assignee's successors and assigns.

Assignment
U.S. Patent Application No. 16/600,236
PCT International Application No. PCT/US2019/055956
Attorney Docket No. 067461-5205-US & 067461-5205-WO

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____
Matthew BERNETT

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____
John DESJARLAIS

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____
Michael HEDVAT

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____
Suzanne SCHUBBERT

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: 3/26/21 _____
Christine BONZON

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____
Ramano RASHID

IN TESTIMONY WHEREOF, Assignee has signed his/her name on the date indicated.

XENCOR, INC.

Date: _____ By: _____

Name: Basil L. DAHIYAT

Title: President and Chief Executive Officer

ASSIGNMENT OF PATENT APPLICATION

WHEREAS, **Matthew BERNETT**, resident of Monrovia, California, USA, **John DESJARLAIS**, resident of Pasadena, California, USA, **Michael HEDVAT**, resident of Encino, California, USA, **Suzanne SCHUBBERT**, resident of Long Beach, California, USA, **Christine BONZON**, resident of Los Angeles, California, USA and **Rumana RASHID**, resident of Temple City, California, USA, hereinafter referred to as "Assignors", are inventors of the invention described in the following patent applications:

Title of Invention: **PD-1 TARGETED IL-15/IL-15RALPHA FC FUSION PROTEINS AND USES IN COMBINATION THERAPIES THEREOF**

U.S. Patent Application No. **16/600,236**, filed October 11, 2019; and

International Application No. **PCT/US2019/055956**, filed October 11, 2019.

WHEREAS, Xencor, Inc., located at 111 West Lemon Avenue, Monrovia, California, 91016 United States of America hereinafter referred to as "ASSIGNEE," is desirous of acquiring an interest in the invention and application and in any U.S. Letters Patent and Registrations which may be granted on any patent application claiming priority from the same;

For good and valuable consideration, receipt of which is hereby acknowledged by Assignors, Assignors have assigned, and by these presents do assign to Assignee all right, title and interest in and to the invention and application and to all foreign counterparts (including patent, utility model and industrial designs), and in and to any Letters Patent and Registrations which may hereafter be granted on any patent application claiming priority from the same in the United States and all countries throughout the world, and to claim the priority from the application as provided by the Paris Convention. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignors had this Assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.

Assignors further agree that Assignors will, without charge to Assignee, but at Assignee's expense, (a) cooperate with Assignee in the prosecution of U.S. Patent applications and foreign counterparts on the invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including applications and instruments of transfer, and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the invention and improvements in any and all countries, and to vest title thereto in Assignee, or Assignee's successors and assigns.

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____
Matthew BERNETT

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____
John DESJARLAIS

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____
Michael HEDVAT

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____
Suzanne SCHUBBERT

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____
Christine BONZON

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: MARCH 03, 2021

Rumana RASHID

IN TESTIMONY WHEREOF, Assignee has signed his/her name on the dates indicated.

XENCOR, INC.

Date: _____ By: _____

Name: Bassil I. DAHIYAT

Title: President and Chief Executive Officer

ASSIGNMENT OF PATENT APPLICATION

WHEREAS, **Matthew BERNETT**, resident of Monrovia, California, USA, **John DESJARLAIS**, resident of Pasadena, California, USA, **Michael HEDVAT**, resident of Encino, California, USA, **Suzanne SCHUBBERT**, resident of Long Beach, California, USA, **Christine BONZON**, resident of Los Angeles, California, USA and **Rumana RASHID**, resident of Temple City, California, USA, hereinafter referred to as "Assignors", are inventors of the invention described in the following patent applications:

Title of Invention: **PD-1 TARGETED IL-15/IL-15RALPHA FC FUSION PROTEINS AND USES IN COMBINATION THERAPIES THEREOF**

U.S. Patent Application No. **16/600,236**, filed October 11, 2019; and

International Application No. **PCT/US2019/055956**, filed October 11, 2019.

WHEREAS, Xencor, Inc., located at 111 West Lemon Avenue, Monrovia, California, 91016 United States of America hereinafter referred to as "ASSIGNEE," is desirous of acquiring an interest in the invention and application and in any U.S. Letters Patent and Registrations which may be granted on any patent application claiming priority from the same;

For good and valuable consideration, receipt of which is hereby acknowledged by Assignors, Assignors have assigned, and by these presents do assign to Assignee all right, title and interest in and to the invention and application and to all foreign counterparts (including patent, utility model and industrial designs), and in and to any Letters Patent and Registrations which may hereafter be granted on any patent application claiming priority from the same in the United States and all countries throughout the world, and to claim the priority from the application as provided by the Paris Convention. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignors had this Assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.

Assignors further agree that Assignors will, without charge to Assignee, but at Assignee's expense, (a) cooperate with Assignee in the prosecution of U.S. Patent applications and foreign counterparts on the invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including applications and instruments of transfer, and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the invention and improvements in any and all countries, and to vest title thereto in Assignee, or Assignee's successors and assigns.

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____
Matthew BERNETT

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____
John DESJARLAIS

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____
Michael HEDVAT

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____
Suzanne SCHUBBERT


IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____
Christine BONZON

IN TESTIMONY WHEREOF, Assignor has signed his/her name on the date indicated.

Date: _____
Rumana RASHID

IN TESTIMONY WHEREOF, Assignee has signed his/her name on the dates indicated.

Date: March 31, 2021 By: 
Name: Bassil I. DAHIYAT
Title: President and Chief Executive Officer